Protein tyrosine phosphatase PTPL1 suppresses lung cancer through Src/ERK/YAP1 signaling

Jing Wang | Shuanghui Li | Xiujuan Zhang | Ning Zhu |
Ruzetuoheti Yiminniyaze | Liang Dong | Chengwei Li | Wumaier Gulinuer |
Jingwen Xia | Jing Li | Daibing Zhou | Xinning Liu | Youzhi Zhang |
Yuanyuan Zhang | Shengqing Li

Department of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China

Correspondence
Shengqing Li, Department of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, No.12 Urumqi Middle Road, Shanghai, 200040, China. Email: shengqingli@hotmail.com

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81970048; National Science and Technology Major Project, Grant/Award Number: 2020DQ056; Research Foundation for Huashan Hospital Affiliated to Fudan University, Grant/Award Number: 2017QD0078

INTRODUCTION

Despite the advances in medication and therapeutics, lung cancer remains the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, accounting for 85% of all cases.1 The overall 5-year survival rate is less than 20%, and less significant improvement has been made over the past decades.2 Recently, although recent targeted therapies and immunotherapy have improved the situation, the long-term survival of advanced patients is still poor.3 Since lung cancer is a molecularly heterogeneous disease and most patients are already in the advanced stage at the time of diagnosis, early diagnosis could remarkably reduce the mortality of patients. An in-depth understanding of lung cancer pathogenesis may potentially lead to new effective treatments.4

It is well known that protein tyrosine phosphorylation plays an important role in intracellular signaling and cell behaviors including proliferation, apoptosis, invasion, and drug resistance.5,6 It has been determined that the deregulation of the aforementioned signal pathways is related to the development and progression of cancer.6 In contrast to kinases that catalyze phosphorylation of the signal transducers, the roles of protein tyrosine phosphatases (PTPs) have not been clearly

Abstract

Background: To reveal the function of protein tyrosine phosphatase-L1 (PTPL1) in lung adenocarcinoma.

Methods: Lung cancer cell lines were transfected with short hairpin RNA against PTPL1 (shPTPL1 group) or negative control (shmock group). Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used to verify the transfection efficacy. Cell proliferation was analyzed by ethynyldeoxyuridine (EdU), Cell counting kit 8 (CCK8), and colony formation assay after PTPL1 or PTPL1 and yes-associated protein (YAP1) knockdown. The effect of PTPL1 on tumor growth was examined in a xenograft lung cancer model.

Results: PTPL1 was downregulated in various types of lung cancer cell lines. The EdU, CCK8, colony formation assays and investigation using a xenograft lung cancer model indicated that PTPL1 knockdown increased the proliferation of lung cancer cells. Mechanistically, PTPL1 knockdown induced the activation of the Proto-oncogene tyrosine-protein kinase SRC (Src)/Extracellular regulated MAP kinase (ERK) pathway and thereby promoted yes-associated protein (YAP1) nuclear translocation and activation.

Conclusions: In our study, PTPL1 played a crucial suppressive role in the pathogenesis of lung cancer potentially through counteracting the Src/ERK/YAP1 pathway.
depicted in the past decades. So far, only a few known PTPs have been established as oncogenes or tumor suppressors.\(^8,9\) Human genome sequencing identified 107 PTP genes, 81 of which encode active protein phosphatases.\(^10\) PTP represents an enzyme superfamily subdivided into classical PTPs, dual-specificity PTPs, and low molecular weight PTPs 13, 14.\(^1\) The catalytic domains of the PTP superfamily are highly conserved.\(^12\) In accordance with their critical involvement in orchestrating canonical intracellular signal pathways, PTP mutations have been frequently documented in various malignancies.\(^12\) The classical PTPs are further grouped into receptor and nonreceptor PTPs.\(^12\) Of the receptor PTPs, protein tyrosine phosphatase receptor type T (PTPRT)-regulated signal transducer and activation of transcription 3 (STAT3) signaling and paxillin phosphorylation seem to be critical for head and neck or colorectal tumorigenesis.\(^13\) Protein tyrosine phosphatase receptor type D (PTPRD) suppresses tumors of various tissue origins by inducing apoptosis of cells.\(^14\) Protein tyrosine phosphatase receptor type K (PTPRK) can counteract HER2-induced proliferation of breast cancer cells by inhibiting human epidermal growth factor receptor 2 (HER2) phosphorylation.\(^15\) Protein tyrosine phosphatase receptor type M (PTPRM) is mainly involved in regulating the proliferation and migration of breast and brain cancer cells, while protein tyrosine phosphatase receptor type J (PTPRI) may be a candidate colon tumor suppressor gene. Protein tyrosine phosphatase receptor type B (PTPDB) regulates endothelial cell polarity and vascular permeability through the dephosphorylation of substrates such as receptor-2 during angiogenesis.\(^12\)

The mitogen-activated protein kinases (MAPK) pathway has been documented as a regulatory target of PTPs. In particular, PTPN11 inactivates MAPK signaling through dephosphorylation of Src or Sprouty, the inhibitor of reticular activating system (RAS).\(^16\) Protein-tyrosine phosphatase-L1 (PTPL1, also known as tyrosine-protein phosphatase nonreceptor type [PTPN13], fas-associated phosphatase 1 [FAP-1], protein-tyrosine phosphatase-Basophil [PTP-BAS], protein tyrosine phosphatase 1E [PTP1E], and protein tyrosine phosphatase LE [PTPLE]) is a nonreceptor PTP with 2485 amino acid residues and has the largest molecular weight of the known PTPs.\(^16\) PTPL1 is composed of several important domains including the kinase noncatalytic C-leaf domain (KIND), the 4.1/ezrin/radixin/moesin (FERM) domain that usually exists in the peripheral membrane protein family, and the carboxy-terminal catalytic domain. Five PSD-95/CD large/ZO-1 (PDZ) domains located between the FERM domain and the carboxy-terminal catalytic domain.\(^17\) As a protein/protein interaction domain, the PDZ domain catalyzes the dephosphorylation of different protein tyrosine sites and participates in the occurrence and development of various diseases.\(^18\)

Previous studies have found that PTPL1 has mutations or low expression in a variety of tumors, including lung cancer, colon cancer, breast cancer, liver cancer, head and neck tumors.\(^19\)–\(^23\) Interestingly, it acts as a tumor suppressor gene in most tumor types.\(^21\) PTPL1 directly dephosphorylates Src on the active protease 419 (Y419) to regulate the invasiveness of breast cancer cells, suggesting its function of suppressing breast cancer.\(^22\) On the contrary, PTPL1 can protect pancreatic cancer cells from CD95-mediated apoptosis.\(^24\) In addition, PTPL1 can also induce chemoresistance in head and neck cancer.\(^23\) Wang et al. found that PTPL1 inhibited the progression of ovarian cancer by dephosphorylating and stabilizing phospho-inhibitor of kappa Balpha (IkBalpha) and thus impairing nuclear translocation of Nuclear factor kappaB NF-kB.\(^25\) The activation of STAT3 inhibits the expression of PTPN13 in squamous cell lung cancer by recruiting histone deacetylase 5 (HDAC5).\(^19\) MicroRNA-30e-5p negatively regulates PTPL1 to promote the growth of lung adenocarcinoma cells, which eventually affects the survival and recurrence rate of patients.\(^26\)

The present study aimed to investigate the impact of PTPL1 on the proliferation of lung cancer cells. To explore the signaling responsible of its role in carcinogenesis, the activation of MAP kinase-ERK kinase (MEK)/ERK pathway and the expression of yes-associated protein (YAP1), a key oncogenic transcription factor, were examined in PTPL1 knockdown cells. Both in vivo and in vitro investigations have proved that the knockdown of PTPL1 increases the proliferation of lung cancer cells and induces the activation of the Src/ERK/YAP1 signaling pathway.

**METHODS**

**Cell culture**

Human NSCLC cell lines A549, NCI-H1975(H1975), BEAS-2B and human embryonic kidney cell HEK293T were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in growth medium (GM) consisting of Dulbecco’s Modified Eagle Medium (DMEM, Gibco) and Roswell Park Memorial (RPMI-1640 medium, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco), 100 μg/ml streptomycin and 100 U/ml penicillin under a humidified atmosphere of 5% CO\(_2\) at 37°C.

**Reverse transcription-polymerase chain reaction (RT-PCR) and quantitative PCR analyses**

Total RNA extraction was performed using a RNase kit (Yeasen), according to the manufacturer’s protocol. RNA purity and concentration were assessed with the Nano Drop 1000 Spectrophotometer (Thermo Fisher Scientific). For each RT-PCR reaction, first-strand cDNA was generated from 1 μg of total RNA with the RT master mix (Takara). The SYBR Green Master mix (Roche) was used to perform real-time PCR following instructions stipulated by the manufacturer. All data were normalized to the expression levels of housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) according to the \(2^{-\Delta\Delta Ct}\) method.

**Western blot analysis**

Total protein extraction mainly involved placing the treated cells in radioimmunoprecipitation assay (RIPA) lysis buffer
(Solarbio) supplemented with ProtLytic protease and phosphatase inhibitor cocktail (NCM Biotech) for 30 min at 4°C. The cytoplasmic protein was extracted using a cytoplasmic protein extraction kit (Beyotime Biotechnology). Protein concentration was assessed using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific). Lysates were diluted in 5× laemmli loading buffer, loaded onto 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, proteins were transferred to polyvinylidene fluoride membranes. The blots were placed in 5% BSA blocking solution for 1 h and incubated with primary antibodies at 4°C overnight. The primary antibodies used for western blotting included PTPL1 (Proteintech, 25944-1-AP), Src (Abcam, ab109381), anti-Src (phosphoY419) (Abcam, ab185617), Phospho-p44/42 MAPK (Erk1/2) (CST, #4370), p44/42 MAPK (Erk1/2) (CST, #4695), MEK (CST, #4694), Phospho-MEK1/2 (Ser217/221) (CST, #9154), YAP (CST, #14074), Phospho-YAP (Ser127) (CST, #13008). Tris-buffered saline plus tween 20 (TBST) was used to wash the membranes three times, and horseradish peroxidase (HRP)-conjugated secondary antibody was incubated for 1.5 h at room temperature. TBST was used to wash the excess secondary antibody, and the western blot was visualized by electrogenerated chemiluminescent (ECL) solution, and finally the chemiluminescence imaging system was used for imaging (Tanon). Band densities were quantified by ImageJ software (Wayne Rasband, National Institutes of Health).

**Cell counting kit-8 assay**

Cells were seeded into 96-well dish at an initial density of $2 \times 10^3 - 3 \times 10^3$ cells/well. At 0, 24, 48, or 72 h post-transfection, the culture medium was changed to serum-free medium containing the same doses of CCK8 (10 μl/well) for

**FIGURE 1** Expression of PTPL1 in lung cancer cell lines. (a) qRT-PCR to detect the relative levels of mRNA in five NSCLC cell lines. (b) Western blot detection of protein levels of PTPL1 in various cell lines. All data are representative of three independent experiments and are shown as mean ± SD. **p < 0.001. mRNA, messenger RNA; NSCLC, non-small cell lung cancer; PTPL1, protein-tyrosine phosphatase-L1**

**FIGURE 2** Knockdown of PTPL1 in various cells. (a) The infection efficiency of recombinant lentiviruses was assessed under fluorescence microscope and by qRT-PCR. (b) Knockdown of PTPL1 was validated via western blot analyses. Data shown are mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; mRNA, messenger RNA; PTPL1, protein-tyrosine phosphatase-L1; shmock, negative control; shPTPL1, short hairpin RNA against PTPL1
an additional 2 h for 37°C. The absorbance at the wavelength of 450 nm using Thermo Multiskan GO (Thermo Scientific) was then recorded to assess cell proliferation.

**Colony formation assay**

Cells were collected in the logarithmic growth phase, and a suspension prepared with a concentration of 2000 cells/6-well plate. The culture dish was placed in an incubator at 37°C and 5% carbon dioxide. After culturing in complete medium for 7 days, the cells were fixed with 4% paraformaldehyde for 30 min, and then stained with 0.1% crystal violet solution (Sigma-Aldrich). After washing the excess dye with phosphate buffered saline (PBS), a microscope was used to detect the total number of colonies with a minimum of 80 cells, and the data recorded and analyzed.

**EdU incorporation assay**

Ethynyldeoxyuridine (EdU) detection kit (Beyotime Biotechnology) was used to assess cell proliferation according to the manufacturer’s instructions. Cells were cultured at 1 × 10^5 cells/well in a 6-well dish. EdU-labeled medium was added to the 6-well dish, and then incubated for 2 h at 37°C and 5% carbon dioxide. Cells were fixed with 4% paraformaldehyde for 30 min at room temperature, followed by permeabilization in 0.5% Triton X-100 at room temperature. Then, 500 μl of anti-EdU working solution was added to each well and incubated for 30 min under light-shading conditions. After washing three times with PBS, the nuclei were counterstained with Hoechst 33342 for 10 min at room temperature. Finally, EdU-labeled cells were observed by a fluorescence microscope (Bio-Rad). The EdU incorporation rate was calculated as the ratio of EdU positive cells (red cells) to the total number of Hoechst 33342 positive cells (blue cells).

**shRNA lentiviral vector construction and transduction**

To silence PTPL1 and YAP1, cells were transduced with short hairpin (shRNA) lentivirus targeting the human PTPN13 gene (Gene ID: 5783) and YAP1 (Gene ID: 10413) with lentivirus recombinant interfering plasmid (pGCSil)-green fluorescent protein (GFP) for transduction rate evaluation. Lentivirus lacking the shRNA insert was used as a control. Cells were seeded into a 6-well dish at a density of 1 × 10^5 cells/well and transduced with shRNA-PTPL1 (6 × 10^8 TU/ml) shRNA-YAP1 (6 × 10^8 TU/ml) or shRNA-mock lentivirus (6 × 10^8 TU/ml). After transfection for 48 h, the cells were imaged under a
fluorescence microscope and further selection by puromycin. Seven days post-infection, PTPL1 and YAP1 silencing was verified through qRT-PCR analysis and western blotting.

**Mouse xenografts**

BALB/c mice were purchased from the Shanghai Slack Laboratory Animal Center. Fifteen 8-week-old nude mice were randomly assigned to three groups, and five mice in each group were independently reared in a 12-h light/dark system to provide sufficient water and clean food. For tumorigenicity assays, $1 \times 10^6$ shmock, shPTPL1, or shPTPL1 + shYAP1 cells were resuspended in 100 μl of PBS. Underarm injections of 8 weeks old male or female nude mice as described previously. The bodyweight and tumor size were measured every 3 days, and the tumor size was measured manually using calipers. All animals were used in compliance with the guidelines approved by the Institutional Animal Care and Use Committee. On the 30th day, the mice were anesthetized to obtain tumor tissue samples and stored in liquid nitrogen.

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism8.0 (GraphPad Software, Inc.). Each experiment was repeated three times and all values are expressed as mean ± SD. Image J software was used for Western blot pattern grayscale scanning. A $t$-test was used to compare the data between the two groups, and the analysis of variance was used to compare the data between multiple groups. $p < 0.05$ was considered statistically significant.

**RESULTS**

Silencing of PTPL1 promotes the proliferation of NLCSC cells

To examine the function of PTPL1 in lung cancer, we assessed its expression in a normal human bronchial...
epithelial cell line, Human Normal Lung Epithelial cells (BEAS-2B), and NLCSC cell lines, H1299, H1650, PC-9, H1975 and A549. We found that PTPL1 knockdown caused significantly improved Src activation and concurrently PTPL1 levels were significantly lower in NSCLC cells than in BEAS-2B cells (Figure 1), indicating a potential role in NSCLC pathogenesis. We next infected cells with recombinant lentiviruses expressing PTPL1-targeted short hairpin RNAs (sh-PTPL1), and validated efficient PTPL1 knockdown via qRT-PCR and Western blot (Figure 2a,b). Consequently, cell proliferation was enhanced by knockdown of PTPL1 in these cells, as revealed by CCK8 assay (Figure 3a). We also used clone formation and Ethynyldeoxyuridine (EdU) assays to investigate the role of PTPL1 in the proliferation of lung cancer cells. Compared with the control group, PTPL1 knockdown significantly increased the proliferation of cells (Figure 3b,c). Collectively, these results indicate that PTPL1 downregulation contributes to the over-proliferation of NSCLC cells.

PTPL1 attenuates phosphorylation of ERK and inactivates YAP1 in NSCLC cells

PTPL1 was reported to repress cell proliferation through dephosphorylating Src, a non-receptor tyrosine kinase known to activate canonical signal pathways including MEK/ERK, and YAP1 is a key oncogenic transcription factor regulated by various signaling such as MEK/ERK pathway. We thus investigated the effects exerted by PTPL1 on the phosphorylation status of Src, MEK, ERK and YAP1 in NSCLC cells. We observed that PTPL1 knockdown A549 cells exhibited consistently increased levels of phosphorylated Src and ERK when cells were exposed to serum or EGF (Figure 4a). In parallel, with the increased phosphorylation of Src and MEK, nuclear YAP1 levels were significantly upregulated after knockdown of PTPL1 in A549 cells (Figure 4b). Thus, PTPL1 knockdown promotes YAP1 nuclear translocation and activation possibly via MEK/ERK pathway in NSCLC cells.

YAP1 silencing reversed the hyperproliferation of NSCLC cells after PTPL1 knockdown

To examine the potential role of YAP1 in the pathogenesis of NSCLC and figure out whether there is an interaction relationship between YAP1 and PTPL1. Next, we infected cells with recombinant lentivirus expressing YAP1 targeting short hairpin RNA (sh-YAP1) and verified the efficient knockout of YAP1 by qRT PCR and Western blot (Figure 5). Therefore, as shown by CCK8 assay, knockdown of YAP1 in these cells reversed cell proliferation in the short hairpin RNA against
FIGURE 6  PTPL1 inhibits growth of lung cancer in vitro through downregulation of YAP1. (a) Cell counting kit-8 (CCK8) assays of control and YAP1 knockdown cells. *p < 0.05 compared with control group. (b) Cell proliferation was analyzed by immunofluorescence staining for EdU. (c) Cell proliferation was analyzed by colony formation assay. Knockdown of YAP1 expression alleviates the inhibition of cell proliferation by PTPL1 in NSCLC cells. Scale bar = 20 μm or (EdU) 100 μm (colony). Data shown are mean ± SD (n = 5). (*p < 0.05, **p < 0.01, ***p < 0.001). EdU, ethynyldeoxyuridine; NSCLC, non-small cell lung cancer; PTPL1, protein-tyrosine phosphatase-L1; shmock, negative control; shPTPL1, short hairpin RNA against PTPL1; shmock, negative control; shPTPL1, short hairpin RNA against PTPL1; shYAP1, short hairpin RNA against YAP1; YAP1, yes-associated protein

FIGURE 7  PTPL1 inhibits growth of xenograft lung cancer in vivo through downregulation of YAP1. (a) Mice were subcutaneously challenged by parental A549 cells, those subjected to PTPL1 or concurrent YAP1 knockdown (n = 5), and the bodyweights of mice were monitored. (a–c) A549 cells treated with sh-mock lentivirus were subcutaneously inoculated to the flanks, shPTPL1 and shPTPL1 + shYAP1 lentivirus were treated to the flanks of nude mice. The tumor growth curves showed that compared with the sh-mock group, the sh-PTPL1 group inhibited tumor growth. (b) The tumor volumes of nude mice described in (a) measured and plotted. (c) Mice in (a) were sacrificed 28 days after inoculation, and tumors were isolated and weighed. The displayed data is the average ± SD (n = 5). (*p < 0.05, **p < 0.01, ***p < 0.001). PTPL1, protein-tyrosine phosphatase-L1; shmock, negative control; shPTPL1, short hairpin RNA against PTPL1; shYAP1, short hairpin RNA against YAP1; YAP1, yes-associated protein
PTPL1 (shPTPL1 group) (Figure 6a). We also used clonogenic and EdU analysis to investigate the role of YAP1 in lung cancer cell proliferation. Compared with shmock, PTPL1 knockdown significantly increased cell proliferation, while the excessive proliferation of cells was reversed after YAP1 knockdown (Figure 6b,c). Taken together, these results indicate that YAP1 downregulation reverses the hyperproliferation of shPTPL1 cells.

PTPL1 and YAP1 dictate tumor growth in a xenograft lung cancer model

We next evaluated whether PTPL1 and downstream signaling played a role in vivo lung cancer development. Nude mice were subcutaneously injected with control A549 cells or those subjected to PTPL1 or concurrent YAP1 knockdown. Within 30 days, all mice developed visible subaxillary solid tumors and exhibited comparable bodyweights (Figure 7a,b) While PTPL1 knockdown significantly promoted the growth of xenograft tumors, further silencing of YAP1 counteracted the effect of PTPL1 knockdown on tumor development (Figure 7b,c). These data suggest that PTPL1 represses in vivo development of lung cancer via downregulation of YAP1.

DISCUSSION

In this study, we demonstrated that the expression of the PTP, PTPL1, was reduced in lung cancer cells compared with normal lung epithelial cells. Moreover, we evaluated the impact of PTPL1 in lung cancer cell proliferative using in vitro and animal models and dissected the molecular mechanism responsible for this effect. We found that PTPL1 impaired the proliferation of lung cancer cells, and silencing of PTPL1 led to increased tumor growth in athymic mice. These results suggest that PTPL1 functions as a potent suppressor in the occurrence of NSCLC. This is also consistent with previous reports that PTPs plays an important role in inhibiting or controlling growth as a tumor suppressor.

Although it is largely uncharacterized how PTPL1 fine-tunes intracellular signaling that controls mitosis, this has been addressed by several previous studies. PTPL1 was found to regulate the cell cycle and upregulate genes related to invasion in prostate cancer cells. PTPL1 acts as a negative regulator of the insulin-like growth factor (IGF)-1R/IRS-1/Akt pathway in breast cancer cells and inhibits fat formation. The loss of PTPL1 in prostate cancer cells may contribute to apoptosis resistance and tumor progression. Depletion of PTPL1 in mice caused increased incidence of breast cancer and accelerated tumor growth in vivo. These findings unraveled a multifaceted role of PTPL1 in suppressing tumorigenesis, highlighting the importance of identifying novel players in PTPL1-regulated network in the context of vital malignancies like lung cancer.

The Hippo pathway is one of the most frequently altered signaling pathways in human cancer. Targeting the core YAP1/TAZ-binding motif-TEA domain family member 1 (TAZ-TEAD) complex in this pathway has the potential to remarkably suppress tumorigenesis. TEAD activity is necessary for maintaining cell proliferation and renewal, and the blockade of YAP1/TAZ binding to TEAD leads to the activation of the Kruppel-like factor 4 (KLF4) transcription network. Furthermore, KLF4 knockout mice showed an increased incidence of cancer. YAP1 has been established to function as a critical oncoprotein in NSCLC. Here, the phenotypic results of the double knockdown cell lines showed that YAP1 promoted the proliferation of NSCLC cells. In vitro experiments showed that YAP1 knockdown reduced the tumorigenic ability of nude mice. Previous studies have also shown that YAP1 was related to the proliferation of various cell types. The N6-methyladenosine demethylase AlkB homolog5 (ALKBH5) inhibited tumor growth by reducing YTH domain-containing-proteins (YTHDFs)-mediated YAP1 expression and inhibiting miR-107/large tumor suppressor kinase 2 (LATS2)-mediated YAP1 activity in NSCLC. The long non-coding RNA, MALAT1, can upregulate YAP1 through sponging miR-194-3p, and thereby induce drug resistance of NSCLC. YAP/TAZ was also found to play an important role in regulating alveolar regeneration and alleviation of lung inflammation. In line with these observations, we found that YAP1 could be upregulated via MEK/ERK signaling in response to PTPL1 deficiency. Although the detailed mechanisms remain elusive, ERK has been documented to serve as a crucial regulator of YAP1. Since YAP1 has also been reported to activate the MEK/ERK pathway, it is likely that they form a feedback regulatory loop to reinforce oncogenic signaling. Finally, our findings do not rule out the probability that other mediators also play indispensable roles in the downstream of PTPL1/ERK signaling in NSCLC. Nonetheless, we currently describe a new mechanism by which PTPL1 inhibits pulmonary tumorigenesis, and thus provide candidate targets for clinical therapy and novel biomarkers for prognostic assessment of lung cancer.

AUTHOR CONTRIBUTIONS

JW and SHL performed the experiments, XJZ and RY analyzed data and help conduct partial experiment. NZ, LD and CWL provided helpful discussion and reviewed the manuscript. WG, JWX, JL, DBL and XNL provided guidance on experimental technology and gave suggestions. YZZ and YYZ supervising the study. Shengqing Li designed this study and supervised the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

This study was supported by the grants from the National Natural Science Foundation of China (no. 81970048), Research Foundation for Huashan Hospital Affiliated to Fudan University (no. 2017QD078) and the National Science and Technology Major Project (2020DQ056).
CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

ORCID

Ruzetuheti Yiminniyaze  https://orcid.org/0000-0002-9403-9613
Daibing Zhou  https://orcid.org/0000-0001-7723-1470
Shengqiang Li  https://orcid.org/0000-0002-0570-2656

REFERENCES
1. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachalios N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015 May;21(1):15099.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–49.
3. Yang CJ, Gu L, Shah SA, Yerokun BA, D’Amico TA, Hartwig MG, et al. Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis. Lung Cancer. 2018 Jan;115:75–83.
4. Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction-evidence, pit falls and future perspectives. Nat Rev Clin Oncol. 2021 Mar;18(3):135–51.
5. Huang Y, Zhang Y, Ge L, Lin Y, Kwok HF. The roles of protein tyrosine phosphatases in human cancers. Cancer. (Basel). 2018 Mar 20;10(3):82.
6. Bollu LR, Mazumdar A, Savage MJ, Brown PH. Molecular pathways: targeting protein tyrosine phosphatases in cancer. Clin Cancer Res. 2017 May 23;23(9):2136–42.
7. Wiede F, Lu KH, Du X, Zwijsen MN, Xu R, Goh PK, et al. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov. 2022 Mar 1;12(3):752–73.
8. Jobe F, Patel B, Kuzmanovic T, Makishima H, Yang Y, Przychoden B, et al. Deletion of Ptpn1 induces myeloproliferative neoplasm. Leukemia. 2017 May;31(5):1229–34.
9. Antony J, Zanini E, Kelly Z, Tan TZ, Karali E, Alomary M, et al. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Rep. 2018 Aug;19(8):e45670.
10. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004 Jun 11;117(6):699–711.
11. Wu W, Hale AJ, Lemeer S, den Hertog J Differential oxidation of protein-tyrosine phosphatases during zebrafish caudal fin regeneration. Sci Rep 2017 Aug 16;7(1):8460.
12. Zhao S, Sedwick D, Wang Z. Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene. 2015 Jul 23;34(30):3885–94.
13. Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4060–4.
14. Solomon DA, Kim J-S, Cronin JC, Sibellener Z, Ryken T, Rosenberg SA, et al. Mutual inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 2008;68:10300–6.
15. Lucci MA, Orlandi R, Trulzi T, Tagliaube E, Balsari A, Villa-Moruzzi E. Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol. 2010;32:361–72.
16. Liu X, Qu CK. Protein tyrosine phosphatase SHP-2 (PTPN11) in hematopoiesis and leukemogenesis. J Signal Transduct. 2011;19:5239; 1–8.
17. Abaan OD, Toretsky JA. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 2008 Jun;27(2):205–14.
18. Bilder D. PDZ proteins and polarity: functions from the fly. Trends Genet. 2001 Sep;17(9):511–9.
19. Han XJ, Xue L, Gong L, Zhu SJ, Yao L, Wang SM, et al. Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5. Biomed Res Int. 2013:2013-468963.
20. Zhang Y, Tu Y, Zhao J, Chen K, Wu C. Reversion-induced LIM interaction with src reveals a novel src inactivation cycle. J Cell Biol. 2009 Mar 23;184(6):785–92.
21. Yeh SH, Wu DC, Tsai CY, Kuo TJ, Yu WC, Chang YS, et al. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin Cancer Res. 2006 Feb 15;12(4):1097–108.
22. Révillion F, Puech C, Rabenoelina F, Chalbos D, Peyrat JF, Freiss G. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int J Cancer. 2009 Feb 1;124(3):638–43.
23. Wieckowski E, Atarashi Y, Stanson J, Sato TA, Whiteside TL. FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis. J Cell Biochem. 2007 Jan 1;100(1):16–28.
24. Ungefroren H, Kruse ML, Trauzold S, Roeschmann S, Roeder C, Arlt A, et al. FAP-1 in pancreatic cancer cells: functional and mechanism studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci. 2001 Aug;114(Pt 15):2735–46.
25. Wang Y, Li M, Huang T, Li J. Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting IkBalpha. Oncol Targets Ther. 2018 Oct;30(11):7603–12.
26. Zhuang L, Shou T, Li K, Gao CL, Dang LZ, et al. MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma. J Cell Mol Med. 2017 Nov;21(11):2852–62.
27. Lucero MY, Chan J. Photoacoustic imaging of elevated glutathione in models of lung cancer for companion diagnostic applications. Nat Chem. 2021 Dec;13(12):1248–56.
28. Li P, Silvis MR, Honaker Y, Lien WH, Arron ST, Vasioukhin V. δ-Ecatenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of hippo signaling pathway. Genes Dev. 2016 Apr 1;30(7):798–811.
29. Julien SG, Dubé N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011 Jan;11(1):35–49.
30. Castillo C, Flores ML, Conde JM, Medina R, Torrubia FJ, Iapón MA, et al. Downregulation of protein tyrosine phosphatase PTP1L alters cell cycle and upregulates invasion-related genes in prostate cancer cells. Clin Exp Metastasis. 2012 Apr;29(4):349–58.
31. Gloudu-Lassis M, Dromard M, Chavey E, Puech C, Fajas L, Hendriks W, et al. Downregulation of protein tyrosine phosphatase PTP-BL represses adipogenesis. Int J Biochem Cell Biol. 2009 Nov;41(11):2173–80.
32. Castillo C, Chinchón D, Medina R, Torrubia FJ, Iapón MA, Sáez C. PTP1L and PKCh contribute to proapoptotic signalling in prostate cancer cells. Cell Death Dis. 2013 Apr 4;4(4):e576.
33. Hamyeh M, Bernex F, Larive RM, Naldi A, Urbach S, Simony-Lafontaine J, et al. PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. Theranostics. 2020 Jan 1;10(1):1016–32.
34. Dey A, Varelas X, Guan KL. Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020 Jul;19(7):480–94.
35. Yuan Y, Park J, Feng A, Awasthi P, Wang Z, Chen Q, et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLf4 activity. Nat Commun. 2020 Mar 19;11(1):1472.
36. Vichas A, Riley AK, Nkinsi NT, Kamlapurkar S, Parrish PCR, Lo A, et al. Integrative oncogene-dependency mapping identifies RTT1 vulnerabilities and synergies in lung cancer. Nat Commun. 2021 Aug 9;12(1):4789.
37. Chen Q, Wang H, Li Z, Li F, Liang L, Zou Y, et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. J Hepatol. 2022 Jan;76(1):135–47.

38. Jin D, Guo J, Wu Y, Yang L, Wang X, du J, et al. m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020 Feb 27;19(1):40.

39. Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, et al. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2021 Feb 23;14(1):32.

40. LaCanna R, Liccardo D, Zhang P, Tragesser L, Wang Y, Cao T, et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J Clin Invest. 2019 Apr 15;129(5):2107–22.

41. Aharonov A, Shakked A, Umansky KB, Savidor A, Genzelinakh A, Kain D, et al. ERBB2 drives YAP activation and EMT-like processes during cardiac regeneration. Nat Cell Biol. 2020 Nov;22(11):1346–56.

42. Leach JDG, Vlahov N, Tsantoulis P, Ridgway RA, Flanagan DJ, Gilroy K, et al. Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis. Nat Commun. 2021 Jun 8;12(1):3464.

43. Zhang Y, Wang Y, Zhou D, Wang K, Wang X, Wang X, et al. Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 2021 Jul;40(27):4580–91.